
-
Sweden drowns in discarded fast fashion items
-
Rybakina powers Kazakhstan into Billie Jean King Cup finals
-
Despite US tariffs pause, southern African economies under threat
-
A night at the Geneva opera -- that is a literal snoozefest
-
Cash-strapped Nigerians turn to YouTube for entertainment
-
Two dead as fans, police clash before Copa Libertadores game in Chile
-
Flowers in their hair: Shan boys ordained into Buddhist monkhood
-
Edwards leads Wolves past Grizzlies as playoff race heats up
-
Ancelotti questioned as Real Madrid face Alaves
-
Old foes Bayern and Dortmund face off amid spectre of European exit
-
Early holiday, more fans: Philippines schools adapt to climate change
-
In skies, as on land, European forces face gaps if US pulls back
-
Digital divas: Can Japan's virtual YouTuber craze crack America?
-
WHO pandemic agreement talks face deadline crunch
-
Stocks, dollar sink and gold hits record as Trump tariff panic returns
-
LeMond hails 'one in a million' Pogacar ahead of Paris-Roubaix debut
-
Liverpool can move closer to the title as top five tension mounts
-
Trump admits trade war 'cost' as markets hit
-
AI only just beginning to revolutionize the NBA game
-
Despite Trump pause, overall US tariff rate at highest in a century
-
'A pain that doesn't subside' at funerals for Dominican nightclub disaster victims
-
Panama deal allows US to deploy troops to canal
-
US firm says it brought back extinct dire wolves
-
Grieving Dominicans start burying 220 victims of nightclub disaster
-
Aberg closes strong at 'sneaky hard' Augusta National
-
US auto union praises some Trump tariffs
-
Australian IVF clinic admits embryo mix-up
-
Rose: I've played well enough to win Masters but lack the jacket
-
Rose again enjoys 'luxury' of first-round Masters lead
-
Rose rockets to Masters lead, defending champ Scheffler in pursuit
-
Tesla opens first showroom in oil-rich Saudi
-
Oscars to add new award for stunts
-
Hatton loves being at Masters but 'It's just so hard'
-
'Mistakes can happen': Amorim backs Onana after Lyon nightmare
-
RFK Jr says study will reveal cause of autism 'epidemic'
-
Tourist family, pilot killed in 'tragic' NY helicopter crash
-
No.1 Scheffler makes strong Masters start to defend title
-
Man Utd and Spurs draw in Europa League, Rangers hold Athletic
-
Rose rockets to Masters lead with Scheffler and McIlroy in pursuit
-
Man Utd held late in Lyon after Onana errors in Europa League
-
Man Utd held late in Lyon after Onana errors
-
Wall Street rally fizzles as tariff fears resurface
-
MLS to open 'second phase' of major season overhaul study
-
Argentina braves 24-hour strike as it awaits word on IMF loan
-
Spain's Ballester finds relief in Masters water hazard
-
Porro rescues Postecoglou as Spurs held by Frankfurt
-
Grieving Dominicans start burying 200+ victims of nightclub disaster
-
CONMEBOL proposes one-off 64-team World Cup in 2030
-
Rybakina on form for Kazakhstan in BJK Cup
-
Former Real Madrid coach Leo Beenhakker dies aged 82

Canada health authority approves Pfizer's anti-Covid pill
Canada's health authority said Monday it has approved Pfizer's anti-Covid pill, Paxlovid, for adults at high risk of progressing to serious disease.
The oral treatment was approved after an "expedited review," Health Canada said in a statement on its website, adding that it would continue to monitor its safety and effectiveness.
"No drug, including PAXLOVID TM, is a substitute for vaccination," the statement added.
The drug, which comprises two types of tablet, is the first Covid-19 therapy which can be taken at home, and is potentially a huge step towards ending the pandemic.
"Today's announcement is particularly important as access to easy-to-use treatments could help to reduce the severity of Covid-19 in adults who become newly infected and are at high-risk of progressing to serious illness," said Theresa Tam, Canada's chief public health officer.
The approval comes as Canada, like many countries, has been struggling to contain the Omicron variant of Covid-19.
The French-speaking province of Quebec recently announced it would levy a tax on the unvaccinated, arguing they impose a burden on everyone else.
Paxlovid has so far been authorized in a handful of countries including the United States and Israel, while the European Union has allowed member states to use it ahead of formal approval as an emergency measure against Omicron.
Unlike vaccines, it does not target the ever-evolving spike protein which the coronavirus uses to invade cells.
It should therefore in theory be more variant-proof, and the company has said preliminary lab studies have backed up that hypothesis.
J.Williams--AMWN